H. Gurney

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

R. Motzer, B. Escudier, A. Shah, 2024, ESMO open.

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

A. Balar, P. Grivas, M. S. van der Heijden, 2024, BMC cancer.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

B. Escudier, S. Oosting, S. Bracarda, 2020 .

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

A. Peer, R. Kataria, R. Leibowitz, 2024, BMC cancer.